PMID- 29181186
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201001
IS  - 2049-9450 (Print)
IS  - 2049-9469 (Electronic)
IS  - 2049-9450 (Linking)
VI  - 7
IP  - 5
DP  - 2017 Nov
TI  - Enhanced antitumor effects and improved immune status of dendritic cell and 
      cytokine-induced killer cell infusion in advanced cancer patients.
PG  - 903-910
LID - 10.3892/mco.2017.1415 [doi]
AB  - Little progress has been made in the treatment of advanced cancer. Dendritic 
      cells (DCs) plus cytokine-induced killer (CIK) cells have exhibited antitumor 
      effects. Thus, the aim of the present study was to evaluate the clinical efficacy 
      of DC-CIK cell treatment in patients with advanced cancer. A paired study 
      including 57 patients treated with DC-CIK cells (DC-CIK group) and 33 patients 
      treated with best supportive care alone (BSC group) was performed. The patients 
      in the DC-CIK group were matched to those in the control group in terms of sex, 
      age, tumor type and clinical stage. T-cell subsets were detected and overall 
      survival (OS) was compared between the two groups. The results demonstrated that 
      CD4(+)/CD25(+) and CD8(+)/CD28(-) subsets significantly decreased following 
      DC-CIK immunotherapy (P<0.05). The CD3(+), CD3(+)/CD8(+), CD8(+)/CD28(+) and 
      CD3(+)/CD56(+) T-cell subsets were significantly increased in the DC-CIK group 
      compared with the BSC group, while the CD8(+)/CD28(-) subset was significantly 
      decreased. Univariate analysis demonstrated that a lower CD8(+)/CD28(-) and a 
      higher CD8(+)/CD28(+) ratio were associated with prolonged OS in advanced cancer 
      patients. In addition, DC-CIK treatment administration, age (>60 vs. <60 years), 
      clinical stage and the frequency of CIK treatment significantly affected the OS 
      of patients in the DC-CIK group. A CD8(+)/CD28(-) ratio of <21.12 was found to 
      decrease the hazard ratio (HR) of OS to 0.50 [95% confidence interval (CI): 
      0.29-0.87] and a CD8(+)/CD28(+) ratio >9.04 was found to decrease the HR of OS to 
      0.45 (95% CI: 0.21-0.98). No serious side effects were observed in the DC-CIK 
      group. Taken together, these data indicate that DC-CIK infusions were able to 
      change the ratios of the T-cell subsets, which increased the T helper cell and 
      cytotoxic T lymphocyte subsets, while it decreased regulatory T lymphocyte 
      subsets. Thus, this method of immunotherapy was found to improve the imbalance in 
      the immune system and prolong the OS in patients with advanced cancer.
FAU - Chen, Feng
AU  - Chen F
AD  - Beijing Shijitan Hospital Cancer Center, Capital Medical University, Beijing Key 
      Laboratory for Therapeutic Cancer Vaccines, Beijing 100038, P.R. China.
FAU - Yang, Menghan
AU  - Yang M
AD  - Beijing Shijitan Hospital Cancer Center, Capital Medical University, Beijing Key 
      Laboratory for Therapeutic Cancer Vaccines, Beijing 100038, P.R. China.
FAU - Song, Qingkun
AU  - Song Q
AD  - Beijing Shijitan Hospital Cancer Center, Capital Medical University, Beijing Key 
      Laboratory for Therapeutic Cancer Vaccines, Beijing 100038, P.R. China.
FAU - Wu, Jiangping
AU  - Wu J
AD  - Beijing Shijitan Hospital Cancer Center, Capital Medical University, Beijing Key 
      Laboratory for Therapeutic Cancer Vaccines, Beijing 100038, P.R. China.
FAU - Wang, Xiaoli
AU  - Wang X
AD  - Beijing Shijitan Hospital Cancer Center, Capital Medical University, Beijing Key 
      Laboratory for Therapeutic Cancer Vaccines, Beijing 100038, P.R. China.
FAU - Zhou, Xinna
AU  - Zhou X
AD  - Beijing Shijitan Hospital Cancer Center, Capital Medical University, Beijing Key 
      Laboratory for Therapeutic Cancer Vaccines, Beijing 100038, P.R. China.
FAU - Yuan, Yanhua
AU  - Yuan Y
AD  - Beijing Shijitan Hospital Cancer Center, Capital Medical University, Beijing Key 
      Laboratory for Therapeutic Cancer Vaccines, Beijing 100038, P.R. China.
FAU - Song, Yuguang
AU  - Song Y
AD  - Beijing Shijitan Hospital Cancer Center, Capital Medical University, Beijing Key 
      Laboratory for Therapeutic Cancer Vaccines, Beijing 100038, P.R. China.
FAU - Jiang, Ni
AU  - Jiang N
AD  - Beijing Shijitan Hospital Cancer Center, Capital Medical University, Beijing Key 
      Laboratory for Therapeutic Cancer Vaccines, Beijing 100038, P.R. China.
FAU - Zhao, Yanjie
AU  - Zhao Y
AD  - Beijing Shijitan Hospital Cancer Center, Capital Medical University, Beijing Key 
      Laboratory for Therapeutic Cancer Vaccines, Beijing 100038, P.R. China.
FAU - Zhou, Lei
AU  - Zhou L
AD  - Beijing Shijitan Hospital Cancer Center, Capital Medical University, Beijing Key 
      Laboratory for Therapeutic Cancer Vaccines, Beijing 100038, P.R. China.
FAU - Ren, Jun
AU  - Ren J
AD  - Beijing Shijitan Hospital Cancer Center, Capital Medical University, Beijing Key 
      Laboratory for Therapeutic Cancer Vaccines, Beijing 100038, P.R. China.
LA  - eng
PT  - Journal Article
DEP - 20170919
PL  - England
TA  - Mol Clin Oncol
JT  - Molecular and clinical oncology
JID - 101613422
PMC - PMC5700278
OTO - NOTNLM
OT  - T-cell subsets
OT  - advanced cancer
OT  - cytokine-induced killer cells
OT  - dendritic cells
OT  - immunotherapy
OT  - overall survival
EDAT- 2017/11/29 06:00
MHDA- 2017/11/29 06:01
PMCR- 2017/09/19
CRDT- 2017/11/29 06:00
PHST- 2017/03/06 00:00 [received]
PHST- 2017/07/20 00:00 [accepted]
PHST- 2017/11/29 06:00 [entrez]
PHST- 2017/11/29 06:00 [pubmed]
PHST- 2017/11/29 06:01 [medline]
PHST- 2017/09/19 00:00 [pmc-release]
AID - MCO-0-0-1415 [pii]
AID - 10.3892/mco.2017.1415 [doi]
PST - ppublish
SO  - Mol Clin Oncol. 2017 Nov;7(5):903-910. doi: 10.3892/mco.2017.1415. Epub 2017 Sep 
      19.